Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy

doi:10.5493/wjem.125753

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

(1)

(0)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Exp Med. Sep 20, 2026; 16(3): 125753
Published online Sep 20, 2026. doi: 10.5493/wjem.125753

Full Size Figure Download Figure

Figure 3 Patient-flow diagram (Consolidated Standards of Reporting Trials-style) for the intention-to-collect cohort. R/R: Relapsed or refractory; MM: Multiple myeloma; BCMA: B-cell maturation antigen; CAR-T: Chimeric antigen receptor T-cell; IQR: Interquartile range; PFS: Progression-free survival; PE: Pulmonary embolism; COVID-19: Coronavirus disease 2019.

Citation: Bangolo A, Gill S, Zhang L, Zhao J, Amoozgar B, Reich-Slotky R, Tran J, Vo T, Mariblanca G, Balulescu X, Mcknight S, Patel N, Reed A, Kaur S, Subramanian S, Katyal J, Manikkuttiyil C, Chakov M, Nguyen A, Pashine S, Khalil A, Mathew S, Gill R, Andrews V, Ordonez P, Olson B, Koleng M, Persaud R, Saride HS, Dharsi M, Thach R, Chen W, Shahid M, Weissman S, Siegel D, Parmar H, Biran N, Vesole DH, Phull P. Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy. World J Exp Med 2026; 16(3): 125753
URL: https://www.wjgnet.com/2220-315x/full/v16/i3/125753.htm
DOI: https://dx.doi.org/10.5493/wjem.125753

Bangolo A, Gill S, Zhang L, Zhao J, Amoozgar B, Reich-Slotky R, Tran J, Vo T, Mariblanca G, Balulescu X, Mcknight S, Patel N, Reed A, Kaur S, Subramanian S, Katyal J, Manikkuttiyil C, Chakov M, Nguyen A, Pashine S, Khalil A, Mathew S, Gill R, Andrews V, Ordonez P, Olson B, Koleng M, Persaud R, Saride HS, Dharsi M, Thach R, Chen W, Shahid M, Weissman S, Siegel D, Parmar H, Biran N, Vesole DH, Phull P. Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy. World J Exp Med 2026; 16(3): 125753 [DOI: 10.5493/wjem.125753]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.